GHRP-6

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue, stimulating GH release from the pituitary gland primarily through hypothalamic mechanisms. It binds to two receptors (GHS-R1a and CD36), activating phosphatidylinositol second messenger systems and prosurvival pathways including PI-3K/AKT1. Beyond its GH-releasing properties, extensive preclinical research has demonstrated unexpected cytoprotective effects across multiple organ systems, including cardioprotective, neuroprotective, anti-fibrotic, and wound healing properties. Clinical studies have evaluated GHRP-6's safety and efficacy in various contexts, from growth stimulation in children to neuroprotection in stroke patients. Currently, GHRP-6 is not FDA-approved for therapeutic use and remains classified as a research peptide. It is banned by WADA for athletic competition. The compound is available through research chemical suppliers and compounding pharmacies, though its legal status varies by jurisdiction. The peptide has demonstrated a favorable safety profile in Phase I clinical trials with primarily mild adverse events.

Growth Hormone Stimulation

• Potent GH Release: GHRP-6 stimulates dose-dependent GH secretion in humans, with peak responses of 18.8 μg/L after oral administration in children, comparable to GHRH (20.8 μg/L) ^[9]
• Synergistic Effects: When combined with GHRH, produces striking synergistic GH release far exceeding additive effects in healthy individuals ^[7][8]
• Multiple Administration Routes: Demonstrates GH-releasing activity via intravenous, subcutaneous, intranasal, and oral routes ^[9]

Cardiovascular Protection

• Cardioprotective Properties: Prevents dilated cardiomyopathy and preserves left ventricular systolic function in doxorubicin-treated animals ^[3]
• Mitochondrial Protection: Sustains cellular antioxidant defense, upregulates prosurvival gene Bcl-2, and preserves cardiomyocyte mitochondrial integrity ^[3]
• Ischemia/Reperfusion Protection: Prevents cardiac cell death and left ventricular failure in experimental ischemia scenarios ^[2]

Neuroprotection

• Brain IGF-I Enhancement: Increases brain IGF-I expression in hypothalamus, cerebellum, and hippocampus while activating Akt/Bad survival pathways ^[13]
• Stroke Recovery: Clinical trial showed 79% mortality reduction and favorable neurological outcomes (NIHSS, Barthel, mRS scores) when combined with EGF in acute ischemic stroke patients
• Anti-apoptotic Effects: Augments Bcl-2 protein levels in critical brain regions, providing cellular protection against neuronal death ^[13]

Tissue Repair and Anti-Fibrotic Effects

• Wound Healing: Accelerates wound closure, reduces inflammatory infiltration, and prevents hypertrophic scar formation in 90.5% of treated wounds versus 12.5% in controls ^[10]
• Liver Fibrosis Reduction: Achieves 75% reduction in fibrotic area with 60% reduction in nodularity in experimental liver cirrhosis models ^[2]
• Anti-Fibrotic Mechanisms: Downregulates TGF-β1, PDGF-β, and CTGF while upregulating PPAR-γ expression ^[10]

Clinical Safety Profile

• Phase I Safety: In dose-escalation studies (100-400 μg/kg), GHRP-6 demonstrated excellent tolerability with 23 total adverse events across 12 subjects, all mild in intensity and fully resolved ^[11]
• No Serious Adverse Events: Nine healthy male volunteers completed pharmacokinetic studies without any serious or moderate adverse events at doses up to 400 μg/kg ^[11]
• Clinical Trial Safety: Phase I/II stroke trial admitted up to 30% serious adverse events with proven causality, but treatment was deemed safe for advancing to Phase III trials

Regulatory Status

• Not FDA Approved: GHRP-6 has no FDA-approved indications and was not nominated with adequate support for FDA evaluation; compounded products using GHRP-6 are not eligible for exemptions from FDA approval requirements
• WADA Prohibition: Explicitly banned under S2 category (Peptide Hormones, Growth Factors, Related Substances); athletes subject to anti-doping testing must avoid GHRP-6 entirely
• Research Peptide Status: Available through research chemical suppliers and compounding pharmacies, though legal status varies by jurisdiction

Side Effects

• Appetite Stimulation: Known to increase appetite (hyperphagia), which may be undesirable for some users
• Metabolic Effects: May elevate cortisol levels and affect glucose metabolism; effects on weight gain and fat mass accrual depend on insulin/glucose status ^[14]
• Water Retention: Possible fluid retention reported in some cases
• Pharmacokinetics: Distribution half-life of 7.6 minutes and elimination half-life of 2.5 hours; requires endogenous GHRH for maximal GH response ^[8][11]

Research Gaps

• Long-term Safety Unknown: Comprehensive long-term safety data in humans remains limited; further work needed to understand extended impact on human physiology
• Cancer Risk Unclear: Elevated IGF-1 levels warrant evaluation of cancer incidence and mortality in long-term studies
• Limited Clinical Trials: Despite compelling preclinical evidence, GHRP-6 remains underutilized therapeutically with limited Phase II/III human clinical data